U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Transformed Non-Hodgkin Lymphoma

MedGen UID:
1667822
•Concept ID:
C4726581
•
Neoplastic Process

Definition

Histologic transformation of a usually indolent non-Hodgkin lymphoma to an aggressive non-Hodgkin lymphoma. [from NCI]

Professional guidelines

PubMed

Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.
Reddy N, Savani BN
Biol Blood Marrow Transplant 2011 Sep;17(9):1265-72. Epub 2011 May 11 doi: 10.1016/j.bbmt.2011.05.002. PMID: 21621630Free PMC Article

Recent clinical studies

Etiology

Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
Mei M, Wondergem MJ, Palmer JM, Shimoni A, Hasenkamp J, Tsai NC, Simpson J, Nademanee A, Raubitschek A, Forman SJ, Krishnan AY
Biol Blood Marrow Transplant 2014 Dec;20(12):2072-5. Epub 2014 Jul 29 doi: 10.1016/j.bbmt.2014.07.028. PMID: 25079874
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM, Allen MS, Loberiza FR Jr, Bociek RG, Bierman PJ, Armitage JO, Vose JM
Biol Blood Marrow Transplant 2014 Apr;20(4):536-42. Epub 2014 Jan 14 doi: 10.1016/j.bbmt.2014.01.004. PMID: 24434781
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW
Br J Haematol 2013 Nov;163(4):487-95. Epub 2013 Sep 20 doi: 10.1111/bjh.12570. PMID: 24111533
High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.
Ban-Hoefen M, Kelly JL, Bernstein SH, Liesveld J, Constine L, Becker M, Milner L, Phillips G, Friedberg JW
Leuk Lymphoma 2012 May;53(5):830-5. Epub 2011 Dec 6 doi: 10.3109/10428194.2011.631637. PMID: 22023518Free PMC Article
Expression of DNA mismatch repair proteins in transformed non-Hodgkin's lymphoma: relationship to smoking.
Nandi S, Yu J, Burger AM, Reinert LS, Gartenhaus RB
Leuk Lymphoma 2006 Sep;47(9):1806-12. doi: 10.1080/10428190600652137. PMID: 17064992

Diagnosis

Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
Mei M, Wondergem MJ, Palmer JM, Shimoni A, Hasenkamp J, Tsai NC, Simpson J, Nademanee A, Raubitschek A, Forman SJ, Krishnan AY
Biol Blood Marrow Transplant 2014 Dec;20(12):2072-5. Epub 2014 Jul 29 doi: 10.1016/j.bbmt.2014.07.028. PMID: 25079874
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM, Allen MS, Loberiza FR Jr, Bociek RG, Bierman PJ, Armitage JO, Vose JM
Biol Blood Marrow Transplant 2014 Apr;20(4):536-42. Epub 2014 Jan 14 doi: 10.1016/j.bbmt.2014.01.004. PMID: 24434781

Therapy

Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
Mei M, Wondergem MJ, Palmer JM, Shimoni A, Hasenkamp J, Tsai NC, Simpson J, Nademanee A, Raubitschek A, Forman SJ, Krishnan AY
Biol Blood Marrow Transplant 2014 Dec;20(12):2072-5. Epub 2014 Jul 29 doi: 10.1016/j.bbmt.2014.07.028. PMID: 25079874
Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM, Allen MS, Loberiza FR Jr, Bociek RG, Bierman PJ, Armitage JO, Vose JM
Biol Blood Marrow Transplant 2014 Apr;20(4):536-42. Epub 2014 Jan 14 doi: 10.1016/j.bbmt.2014.01.004. PMID: 24434781
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW
Br J Haematol 2013 Nov;163(4):487-95. Epub 2013 Sep 20 doi: 10.1111/bjh.12570. PMID: 24111533
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.
Roy R, Evens AM, Patton D, Gallot L, Larson A, Rademaker A, Cilley J, Spies S, Variakojis D, Gordon LI, Winter JN
Leuk Lymphoma 2013 Mar;54(3):497-502. Epub 2012 Sep 11 doi: 10.3109/10428194.2012.722215. PMID: 22906230
High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.
Ban-Hoefen M, Kelly JL, Bernstein SH, Liesveld J, Constine L, Becker M, Milner L, Phillips G, Friedberg JW
Leuk Lymphoma 2012 May;53(5):830-5. Epub 2011 Dec 6 doi: 10.3109/10428194.2011.631637. PMID: 22023518Free PMC Article

Prognosis

Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
Mei M, Wondergem MJ, Palmer JM, Shimoni A, Hasenkamp J, Tsai NC, Simpson J, Nademanee A, Raubitschek A, Forman SJ, Krishnan AY
Biol Blood Marrow Transplant 2014 Dec;20(12):2072-5. Epub 2014 Jul 29 doi: 10.1016/j.bbmt.2014.07.028. PMID: 25079874
High-dose therapy and autologous stem cell transplant for transformed non-Hodgkin lymphoma in the rituximab era.
Ban-Hoefen M, Kelly JL, Bernstein SH, Liesveld J, Constine L, Becker M, Milner L, Phillips G, Friedberg JW
Leuk Lymphoma 2012 May;53(5):830-5. Epub 2011 Dec 6 doi: 10.3109/10428194.2011.631637. PMID: 22023518Free PMC Article
Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.
Reddy N, Savani BN
Biol Blood Marrow Transplant 2011 Sep;17(9):1265-72. Epub 2011 May 11 doi: 10.1016/j.bbmt.2011.05.002. PMID: 21621630Free PMC Article
Six of 12 relapsed or refractory indolent lymphoma patients treated 10 years ago with 131I-tositumomab remain in complete remission.
Buchegger F, Antonescu C, Helg C, Kosinski M, Prior JO, Delaloye AB, Press OW, Ketterer N
J Nucl Med 2011 Jun;52(6):896-900. Epub 2011 May 13 doi: 10.2967/jnumed.111.087460. PMID: 21571800
Alteration of SMRT tumor suppressor function in transformed non-Hodgkin lymphomas.
Song L, Zlobin A, Ghoshal P, Zhang Q, Houde C, Weijzen S, Jiang Q, Nacheva E, Yagan D, Davis E, Galiegue-Zouitina S, Catovsky D, Grogan T, Fisher RI, Miele L, Coignet LJ
Cancer Res 2005 Jun 1;65(11):4554-61. doi: 10.1158/0008-5472.CAN-04-4108. PMID: 15930272

Clinical prediction guides

Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM, Allen MS, Loberiza FR Jr, Bociek RG, Bierman PJ, Armitage JO, Vose JM
Biol Blood Marrow Transplant 2014 Apr;20(4):536-42. Epub 2014 Jan 14 doi: 10.1016/j.bbmt.2014.01.004. PMID: 24434781
Bortezomib may be safely combined with Y-90-ibritumomab tiuxetan in patients with relapsed/refractory follicular non-Hodgkin lymphoma: a phase I trial of combined induction therapy and bortezomib consolidation.
Roy R, Evens AM, Patton D, Gallot L, Larson A, Rademaker A, Cilley J, Spies S, Variakojis D, Gordon LI, Winter JN
Leuk Lymphoma 2013 Mar;54(3):497-502. Epub 2012 Sep 11 doi: 10.3109/10428194.2012.722215. PMID: 22906230
Characterization of EBV-genome negative "null" and "T" cell lines derived from children with acute lymphoblastic leukemia and leukemic transformed non-Hodgkin lymphoma.
Schneider U, Schwenk HU, Bornkamm G
Int J Cancer 1977 May 15;19(5):621-6. doi: 10.1002/ijc.2910190505. PMID: 68013

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...